Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

New England Journal of Medicine

Volumn 360, Issue 18, 2009, Pages 1827-1838

  McHutchison, John G ^a,g   Everson, Gregory T ^b   Gordon, Stuart C ^c   Jacobson, Ira M ^d   Sulkowski, Mark ^e   Kauffman, Robert ^f   McNair, Lindsay ^f   Alam, John ^f   Muir, Andrew J ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c HENRY FORD HOSPITAL   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f VERTEX PHARMACEUTICALS   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; TELAPREVIR; VIRUS RNA; ALPHA2A INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; OLIGOPEPTIDE; PEGINTERFERON ALFA-2A;

ADULT; ANEMIA; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RACEMIZATION; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; SCOTOMA; SIDE EFFECT; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE; VIROLOGY; BLOOD; DRUG ADMINISTRATION; DRUG COMBINATION; GENETICS; GENOTYPE; ISOLATION AND PURIFICATION; MIDDLE AGED; MULTICENTER STUDY; RECURRENT DISEASE; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; RECURRENCE; RIBAVIRIN; RNA, VIRAL; VIRAL LOAD; YOUNG ADULT;

EID: 65449152185     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0806104     Document Type: Article

References (21)

1. World Health Organization Initiative for Vaccine Research. Hepatitis C. (Accessed April 6, 2009, at http://www.who.int/vaccine-research/diseases/viral- cancers/en/index2.html.)
2. Di Bisceglie AM, Lyra AC, Schwartz M, et al. Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol 2003;98:2060-2063 (Pubitemid 37185806)
3. Organ Procurement and Transplantation Network. U.S. liver transplants performed: January 1, 1988-April 30, 2008. (Accessed April 6, 2009, at http://www.optn.org/.)
4. World Health Organization. Global surveillance and control of hepatitis C: report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999;6:35-47.
5. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965 (Pubitemid 32913521)
6. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982
7. Sulkowski M, Lawitz E, Shiffman ML, et al. Final results of the phase 3b IDEAL (individualized dosing efficacy versus flat dosing to assess optimal pegylated interferon therapy) phase IIIb study. Presented at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), Milan, April 23-27, 2008. abstract.
8. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004;350:2265-2271 [Erratum, N Engl J Med 2004;351:1268.] (Pubitemid 38669209)
9. Pawlotsky JM, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 2007;132:1979-1998 (Pubitemid 46695724)
10. Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M. The way forward in HCV treatment - finding the right path. Nat Rev Drug Discov 2007;6:991-1000. [Errata, Nat Rev Drug Discov 2008;7:102, 458.] (Pubitemid 350201789)
11. Lin C, Kwong AD, Perni RB. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets 2006;6:3-16. (Pubitemid 43796632)
12. Reesink HW, Zeuzem S, Weegink CJ, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006;131:997-1002. (Pubitemid 44498690)
13. Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007;132:1767-1777 (Pubitemid 46677938)
14. Lawitz E, Rodriguez-Torres M, Muir AJ, et al. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol 2008;49:163-169
15. Forestier N, Reesink HW, Weegink CJ, et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 2007;46:640-648 (Pubitemid 47436108)
16. Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007;46:631-639 (Pubitemid 47436107)
17. Dienstag JL, McHutchison JG. American Gastroenterological Association tech nical review on the management of hepatitis C. Gastroenterology 2006;130:231-264 (Pubitemid 43049856)
18. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-355 (Pubitemid 38268915)
19. Hézode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360:1839-1850.
20. Jacobson IM, Brown RS Jr, Freilich B, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007;46:971-981 (Pubitemid 350144761)
21. Zhou Y, Bartels D, Muh U, et al. Phenotypic characterization of telaprevir (VX-950) NS3 protease variants in a HCV replicon system. Presented at the 13th International Symposium on Hepatitis C Virus and Related Viruses, Cairns, Australia, August 27-31, 2006.